Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-di hydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design (vol 64, pg 12893, 2021)

Mark Sabat, Douglas R. Dougan, Jacques Ermolieff,Petro Halkowycz,Beverly Knight,J. David Lawson,Nicholas Scorah,Christopher R. Smith, Ewan R. Taylor, Phong Vu, Corey Wyrick,Haixia Wang, Deepika Balakrishna,Mark Hixon,Loui Madakamutil, Donavon McConn

JOURNAL OF MEDICINAL CHEMISTRY（2021）

Cited 7|Views12

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined